Skip to content

Resources

The Latest

  • Latest Blog Article

    The Peptide Boom: Why So Many Popular Products Are Still Off-Limits

    Peptides are having a moment. There’s just one problem: Many of the most popular peptides on the market today are not currently permissible under the existing FDA regulatory framework. This post breaks down where these substances actually stand today and what all of this means for LegitScript-certified businesses operating within the US.

    Read More

    September 22, 2026

Explore by Topic ▼

Fraud Risk and Prevention | High Risk and Problematic Products | High Risk Businesses and Services | Regulatory and Card Brand Compliance | E-commerce Risk and Compliance | Healthcare | Addiction Treatment and Recovery Programs | CBD and Cannabis

View All

Webinars
Guides
Videos

Blog Articles
Events
Customer Spotlights

Fraud Risk and Prevention

See more about Fraud Risk and Prevention

  • Latest Blog Article

    Fraud by Prompt: Key Takeaways on Problematic Uses of AI at MRNYC

    From deepfake product photos to AI-generated NCII, trust and safety teams are facing a threat that shifts faster than most policies can keep up with. At Marketplace Risk’s New York conference, a panel of experts broke down the evasion tactics bad actors are using right now, the gray areas that trip up even experienced teams, and what it actually takes to build a policy that holds up.

    Read More

    September 22, 2026

High Risk and Problematic Products

See more about High Risk and Problematic Products

  • Latest Blog Article

    The Next Nicotine Problem: What Trust and Safety Teams Aren’t Watching For

    Nicotine products don’t look like nicotine products anymore, and that’s exactly the problem. Novel products are slipping past standard detection, while a backlogged FDA and a patchwork of state rules make consistent enforcement nearly impossible. A panel at Marketplace Risk’s New York conference dug into where the risk is hiding and what platforms can do.

    Read More

    September 22, 2026

High Risk Businesses and Services

See more about High Risk Businesses and Services

  • Latest Blog Article

    Fraud by Prompt: Key Takeaways on Problematic Uses of AI at MRNYC

    From deepfake product photos to AI-generated NCII, trust and safety teams are facing a threat that shifts faster than most policies can keep up with. At Marketplace Risk’s New York conference, a panel of experts broke down the evasion tactics bad actors are using right now, the gray areas that trip up even experienced teams, and what it actually takes to build a policy that holds up.

    Read More

    September 22, 2026

Regulatory and Card Brand Compliance

See more about Regulatory and Card Brand Compliance

E-commerce Risk and Compliance

See more about E-commerce Risk and Compliance

  • Latest Blog Article

    The Next Nicotine Problem: What Trust and Safety Teams Aren’t Watching For

    Nicotine products don’t look like nicotine products anymore, and that’s exactly the problem. Novel products are slipping past standard detection, while a backlogged FDA and a patchwork of state rules make consistent enforcement nearly impossible. A panel at Marketplace Risk’s New York conference dug into where the risk is hiding and what platforms can do.

    Read More

    September 22, 2026

Addiction Treatment and Recovery Programs

See more about Addiction Treatment and Recovery Programs

Healthcare

See more about Healthcare

  • Latest Blog Article

    The Peptide Boom: Why So Many Popular Products Are Still Off-Limits

    Peptides are having a moment. There’s just one problem: Many of the most popular peptides on the market today are not currently permissible under the existing FDA regulatory framework. This post breaks down where these substances actually stand today and what all of this means for LegitScript-certified businesses operating within the US.

    Read More

    September 22, 2026

CBD and Cannabis

See more about CBD and Cannabis